Sequenom Provides Update On Status Of Patent For Methods Of Detecting Fetal Aneuploidy

 Sequenom Provides Update On Status Of Patent For Methods Of Detecting Fetal

PR Newswire

SAN DIEGO, Dec. 14, 2012

SAN DIEGO, Dec. 14, 2012 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative genetic analysis solutions, today
announced that the U.S. Patent and Trademark Office has withdrawn the issuance
of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and
Trademark Office that issuance was withdrawn in connection with an anticipated
patent interference proceeding between parties with pending patent
applications or issued patents directed to similar subject matter.

Sequenom had previously been notified that the patent would issue on December
25, 2012, with claims to novel methods for detecting fetal aneuploidy using
massively parallel sequencing. The patent is entitled Diagnosing Fetal
Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was
invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University
of Hong Kong.Sequenom has exclusive rights to this patent.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding an anticipated patent
interference proceeding and the Company's commitment to improving healthcare
through revolutionary genetic analysis solutions, are forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties associated with market
demand for and acceptance and use by customers of its products, reliance upon
the collaborative efforts of other parties, the Company's financial position,
its ability to position itself for product launches and growth and develop and
commercialize new technologies and products, particularly newer technologies
such as noninvasive prenatal diagnostics, laboratory developed tests, and
genetic analysis platforms, the Company's ability to manage its existing cash
resources or raise additional cash resources, competition, intellectual
property protection and intellectual property rights of others, government
regulation particularly with respect to diagnostic products and laboratory
developed tests, obtaining or maintaining regulatory approvals, litigation
involving the Company, and other risks detailed from time to time in the
Company's most recently filed Quarterly Report on Form 10-Q and Annual Report
on Form 10-K for the year ended December 31, 2011, and other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. These forward-looking statements are based on current information
that may change and you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation to revise
or update any forward-looking statement to reflect events or circumstances
after the issuance of this press release.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028,, or Jakob Jakobsen,
Media Contact, Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.